Akero is growing due to planned publication data in the middle stage of the property of liver disease


Hepatitis virus with human liver

Rasi Bhadrami

  • Akero Therapeutics (Nasdaq:Acre) is Up ~ 5% In trading after working hours on Friday after announcing that the conference call 27. January in order to discuss the main results of the 2B Efruxiferminal Studies in patients with compensated cirrhosis due to metabolic



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *